AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

The Nikkei 225 Futures was launched at Singapore Exchange (SGX) in 1986, the Osaka Securities Exchange (OSE) in 1988 & Chicago Mercantile Exchange (CME) in 1990. The Nikkei average hit its all ...